Headquartered in Singapore, Takeda's Growth & Emerging Markets Business Unit (GEM BU) has presence in almost 50 geographies that includes Brazil, China and Russia, and Area operations with hubs in Asia Pacific, ICMEA, and SAM*.
We are committed to addressing patient unmet medical needs in the GEM region, which includes those parts of the world with some of the heaviest healthcare burdens. We are primarily focused on delivering medical innovation to patients in the areas of Oncology, Gastroenterology, Plasma Derived Therapies, and Rare Diseases.
Brazil, China and Russia, and our three Area operations, are of particular focus as part of the Region’s ambition to deliver sustainable, profitable growth via our commercial activities, and to increase the number of patient lives positively impacted via Takeda’s global Access to Medicines strategy.
The BU aspires to be viewed as 'Best in Class' in the eyes of patients, customers and its own employees. Over the recent years, several of its local offices across the region have been externally recognized as ‘Top Employer’ by the Top Employer Institute.
*APAC - Asia Pacific
ICMEA - India, CIS, the Middle East, including Turkey, & Africa
SAM - South Cone, Andean and Mexico & CAC (Central America & Caribbean)
8 Marina Boulevard, #15-01 Marina Bay Financial Centre, Singapore 018981